EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies

Sarmishta Majumdar, Ranjeet Desai, Aakarsh Hans, Prajakta Dandekar, Ratnesh Jain

Molecular Biotechnology · 2025

DOI: 10.1007/s12033-024-01060-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Sarmishta Majumdar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science and Biotechnology, Institute of Chemical Technology, Mumbai, 400019, India. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Cricetulus, Recombinant Proteins. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: University Grants Commission, Council of Scientific and Industrial Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing demand for biosimilar monoclonal antibodies (mAbs) has prompted the development of stable high-producing cell lines while simultaneously decreasing the time required for screening. Existing platforms have proven inefficient, resulting in inconsistencies in yields, growth characteristics, and quality features in the final mAb products. Selecting a suitable expression host, designing an effective gene expression system, developing a streamlined cell line generation approach, optimizing culture conditions, and defining scaling-up and purification strategies are all critical steps in the production of recombinant proteins, particularly monoclonal antibodies, in mammalian cells. As a result, an active area of study is dedicated to expression and optimizing recombinant protein production. This review explores recent breakthroughs and approaches targeted at accelerating cell line development to attain efficiency and consistency in the synthesis of therapeutic proteins, specifically monoclonal antibodies. The primary goal is to bridge the gap between rising demand and consistent, high-quality mAb production, thereby benefiting the healthcare and pharmaceutical industries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCricetulusRecombinant ProteinsAnimalsCHO CellsHumansBiosimilar PharmaceuticalsCell Culture Techniques

Stichwörter der Autor:innen

BiosimilarsCHOCell line developmentExpression vectorGenetic engineering

Substanzen

Antibodies, MonoclonalRecombinant ProteinsBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Biological Science and Biotechnology, Institute of Chemical Technology, Mumbai, 400019, India.
  • Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, 400019, India.
  • Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, 400019, India. pd.jain@ictmumbai.edu.in.
  • Department of Biological Science and Biotechnology, Institute of Chemical Technology, Mumbai, 400019, India. rd.jain@ictmumbai.edu.in.

Förderung

  • University Grants Commission
  • Council of Scientific and Industrial Research, India

Zitieren

APA

Majumdar, S., Desai, R., Hans, A., Dandekar, P., & Jain, R. (2025). From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01060-6

Vancouver

Majumdar S, Desai R, Hans A, Dandekar P, Jain R. From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01060-6

BibTeX
@article{Majumdar2025,
  author = {Majumdar, Sarmishta and Desai, Ranjeet and Hans, Aakarsh and Dandekar, Prajakta and Jain, Ratnesh},
  title = {From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies},
  journal = {Molecular Biotechnology},
  year = {2025},
  doi = {10.1007/s12033-024-01060-6}
}
Kostenlos starten →